MBF-015CT-02
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients
Phase 2 study testing MBF-015 in Huntington's disease.
Temporarily haltedPhase IINot specifiedCTIS (EU)Treatment trial
- EU sites are temporarily halted (CTIS (EU))
Recruiting in: Spain
Sponsor: Medibiofarma S.L.
Preparing a short plain-English summary.